Physician profile
Sandra Roberson
NPI 1023042140
$4,634.07
in general payments reported to CMS, 2019-2025
22 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $94.21 · 2021: $15.39 · 2022: $545 · 2023: $1,082 · 2024: $829 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,283 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.28 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,285.48 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $799.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $436.73 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $400.59 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $310.32 | 2019-2025 | |
| Csl Behring | $222.20 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Kaleo, INC. | $211.54 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $141.61 | 2022-2025 | Xembify |
| Teva Pharmaceuticals USA, INC. | $134.54 | 2019-2023 | |
| Optinose US, INC. | $108.20 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $104.49 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $85.86 | 2023-2025 | Cuvitru, Glassia |
| Biocryst US Sales Co., LLC | $84.80 | 2024-2025 | Orladeyo |
| Amgen INC. | $62.09 | 2025 | Tezspire |
| Abbvie INC. | $57.39 | 2022-2023 | Rinvoq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $40.37 | 2019 | |
| Pfizer INC. | $31.63 | 2019 | |
| Pharming Healthcare, INC. | $27.56 | 2024 | Ruconest |
| Merck Sharp & Dohme LLC | $25.91 | 2023 | |
| Organon LLC | $23.52 | 2025 | Vtama |
| Cycle Pharmaceuticals INC | $23.38 | 2025 | Sajazir |
| Lilly USA, LLC | $16.45 | 2024 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.